Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06130046
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
Sponsor: University of Rome Tor Vergata
View on ClinicalTrials.gov
Summary
To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2022-12-01
Completion Date
2026-12-01
Last Updated
2025-08-01
Healthy Volunteers
No
Interventions
BIOLOGICAL
MR-proADM dosage
Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U
Locations (1)
University of Rome Tor Vergata
Rome, Italy